Navigation Links
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Date:6/26/2009

BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of the study point out.

Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.

"Given the extensive clinical evidence covering over 70,000 patients and the results of post-marketing surveillance arising from 24 million patient-years of experience, sanofi-aventis stands behind the safety of Lantus(R)," said Jean-Pierre Lehner, M.D., Chief Medical Officer. "We consider that the results of these patient registries are not conclusive."

Patient safety is the primary concern of sanofi-aventis. The Group will continue to vigorously monitor the safety of Lantus(R) in close collaboration with regulatory agencies and scientific experts.

About Diabetes

Diabetes is a chronic, widespread condition in which the body does not produce or properly use insulin, the hormone needed to transport glucose (sugar) from the blood into the cells of the body for energy. More than 230 million people worldwide are living with the disease and this number is expected to rise to a staggering 350 million within 20 years. It is estimated that nearly 24 million Americans have diabetes, including an estimated 5.7 million who remain undiagnosed. At the same time, approximately 40 percent of those diagnosed are not achieving the blood sugar control target of HbA1c <7 percent recommended by the ADA. The HbA1c test measures average blood glucose levels over the past two- to three-month period.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Contact: Lisa Buffington - sanofi-aventis, +1-908-981-6569, lisa.buffington@sanofi-aventis.com


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
3. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
6. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
7. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
8. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus
9. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
10. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
11. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... Summary GlobalData,s new report, "Australia Glaucoma ... market data on the Australia Glaucoma Surgery Devices ... US dollars, volume (in units) and average prices ... The report also provides company shares and ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society ... the summer of 2016. The program was made possible by a Pennsylvania Department ... of Health and Human Services Administration. The broadcast, Use Your Head: Properly ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Institute (WCRI) officially opened registration today for its 33rd Annual Issues & ... MA . , The theme of the conference is “Persistent Challenges and New ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
Breaking Medicine News(10 mins):